康弘药业：关于子公司收到药物临床试验批准通知书的公告

Group 1 - The core announcement is that Kanghong Pharmaceutical's wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug KH816 injection [2] Group 2 - The approval signifies a significant step in the development of KH816 injection, indicating potential advancements in the company's product pipeline [2] - This development may enhance the company's position in the pharmaceutical industry, particularly in the area of innovative drug therapies [2] - The news reflects the regulatory progress and commitment of the company towards bringing new treatments to market [2]